Journal of Neurology

, Volume 263, Issue 7, pp 1390–1400 | Cite as

A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease

  • Jose Luis López-Sendón MorenoEmail author
  • Juan García Caldentey
  • Patricia Trigo Cubillo
  • Carolina Ruiz Romero
  • Guillermo García Ribas
  • M. A. Alonso Alonso Arias
  • María Jesús García de Yébenes
  • Rosa María Tolón
  • Ismael Galve-Roperh
  • Onintza Sagredo
  • Sara Valdeolivas
  • Eva Resel
  • Silvia Ortega-Gutierrez
  • María Laura García-Bermejo
  • Javier Fernández Ruiz
  • Manuel Guzmán
  • Justo García de Yébenes Prous
Original Communication


Huntington’s disease (HD) is a neurodegenerative disease for which there is no curative treatment available. Given that the endocannabinoid system is involved in the pathogenesis of HD mouse models, stimulation of specific targets within this signaling system has been investigated as a promising therapeutic agent in HD. We conducted a double-blind, randomized, placebo-controlled, cross-over pilot clinical trial with Sativex®, a botanical extract with an equimolecular combination of delta-9-tetrahydrocannabinol and cannabidiol. Both Sativex® and placebo were dispensed as an oral spray, to be administered up to 12 sprays/day for 12 weeks. The primary objective was safety, assessed by the absence of more severe adverse events (SAE) and no greater deterioration of motor, cognitive, behavioral and functional scales during the phase of active treatment. Secondary objectives were clinical improvement of Unified Huntington Disease Rating Scale scores. Twenty-six patients were randomized and 24 completed the trial. After ruling-out period and sequence effects, safety and tolerability were confirmed. No differences on motor (p = 0.286), cognitive (p = 0.824), behavioral (p = 1.0) and functional (p = 0.581) scores were detected during treatment with Sativex® as compared to placebo. No significant molecular effects were detected on the biomarker analysis. Sativex® is safe and well tolerated in patients with HD, with no SAE or clinical worsening. No significant symptomatic effects were detected at the prescribed dosage and for a 12-week period. Also, no significant molecular changes were observed on the biomarkers. Future study designs should consider higher doses, longer treatment periods and/or alternative cannabinoid combinations. identifier: NCT01502046


Huntington’s disease Cannabinoid Sativex Clinical trial 



We thank the patients and their families who participated in the trial for their endeavor. We also thank GW Pharmaceuticals for their kind support.

Compliance with ethical standards

Funding sources for the study

This study was sponsored by Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal, GW Pharmaceuticals Ltd and Comunidad de Madrid (Grant S2010/BMD-2308).

Financial disclosure

García Caldentey, J, Trigo Cubillo, P; Ruiz Romero, C; García Ribas, G; Alonso Arias, MA; García de Yébenes M.J; Tolón Rafael, RM; Galve-Roperh, I; Resel, E; Ortega-Gutierrez, S; García-Bermejo, ML; Guzmán, M; García de Yébenes Prous, J report no disclosures.

Conflicts of interest

López-Sendón Moreno J.L.: has received travel grants from Lundbeck and Krka pharmaceuticals. No conflicts of interest to disclose. Sagredo O, Valdeolibas S and Fernández-Ruiz J are recipient of a grant from GW Pharmaceuticals.

Supplementary material

415_2016_8145_MOESM1_ESM.doc (67 kb)
Supplemental Data (Fig. 1, Supplementary Material: Consort Flow Diagram; Table 1, Supplementary Material: Basal Clinic Characteristics) (DOC 67 kb)
415_2016_8145_MOESM2_ESM.doc (43 kb)
Supplementary material 2 (DOC 43 kb)


  1. 1.
    Walker FO (2007) Huntington’s disease. Lancet 369(9557):218–228CrossRefPubMedGoogle Scholar
  2. 2.
    The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72(6):971–983CrossRefGoogle Scholar
  3. 3.
    Rosas HD, Salat DH, Lee SY et al (2008) Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain 131(Pt 4):1057–1068CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Marsicano G, Goodenough S, Monory K et al (2003) CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302(5642):84–88CrossRefPubMedGoogle Scholar
  5. 5.
    Cota D (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23(7):507–517CrossRefPubMedGoogle Scholar
  6. 6.
    Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89(1):309–380CrossRefPubMedGoogle Scholar
  7. 7.
    Wright S (2007) Cannabinoid-based medicines for neurological disorders–clinical evidence. Mol Neurobiol 36(1):129–136CrossRefPubMedGoogle Scholar
  8. 8.
    Fernandez-Ruiz J (2009) The endocannabinoid system as a target for the treatment of motor dysfunction. Br J Pharmacol 156(7):1029–1040CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pazos MR, Sagredo O, Fernandez-Ruiz J (2008) The endocannabinoid system in Huntington’s disease. Curr Pharm Des 14(23):2317–2325CrossRefPubMedGoogle Scholar
  10. 10.
    Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M (2007) Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28(1):39–45CrossRefPubMedGoogle Scholar
  11. 11.
    Fernandez-Ruiz J, Garcia C, Sagredo O, Gomez-Ruiz M, de Lago E (2010) The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14(4):387–404CrossRefPubMedGoogle Scholar
  12. 12.
    Pertwee RG (2009) Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156(3):397–411CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Gowran A, Noonan J, Campbell VA (2011) The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 17(6):637–644CrossRefPubMedGoogle Scholar
  14. 14.
    Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30(3):313–327CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11(2):563–583PubMedGoogle Scholar
  16. 16.
    Nunez E, Benito C, Tolon RM, Hillard CJ, Griffin WS, Romero J (2008) Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down’s syndrome. Neuroscience 151(1):104–110CrossRefPubMedGoogle Scholar
  17. 17.
    Toth A, Blumberg PM, Boczan J (2009) Anandamide and the vanilloid receptor (TRPV1). Vitam Horm 81:389–419CrossRefPubMedGoogle Scholar
  18. 18.
    van der Stelt M, Veldhuis WB, Maccarrone M et al (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26(2–3):317–346CrossRefPubMedGoogle Scholar
  19. 19.
    Chiarlone A, Bellocchio L, Blazquez C et al (2014) A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci USA 111(22):8257–8262CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Palazuelos J, Aguado T, Pazos MR et al (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132(Pt 11):3152–3164CrossRefPubMedGoogle Scholar
  21. 21.
    Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95(14):8268–8273CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Muller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington’s disease. Mov Disord 14(6):1038–1040CrossRefPubMedGoogle Scholar
  23. 23.
    Curtis A, Rickards H (2006) Nabilone could treat chorea and irritability in Huntington’s disease. J Neuropsychiatry Clin Neurosci 18(4):553–554CrossRefPubMedGoogle Scholar
  24. 24.
    Curtis A, Mitchell I, Patel S, Ives N, Rickards H (2009) A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov Disord 24(15):2254–2259CrossRefPubMedGoogle Scholar
  25. 25.
    Consroe P, Laguna J, Allender J et al (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav 40(3):701–708CrossRefPubMedGoogle Scholar
  26. 26.
    Russo E, Guy GW (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66(2):234–246CrossRefPubMedGoogle Scholar
  27. 27.
    Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernandez-Ruiz J, Brouillet E (2004) Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. NeuroReport 15(15):2375–2379CrossRefPubMedGoogle Scholar
  28. 28.
    Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernandez-Ruiz J (2007) Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 26(4):843–851CrossRefPubMedGoogle Scholar
  29. 29.
    Valdeolivas S, Satta V, Pertwee RG, Fernandez-Ruiz J, Sagredo O (2011) Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3(5):400–406CrossRefGoogle Scholar
  30. 30.
    Huntington Study Group (1996) Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136–142CrossRefGoogle Scholar
  31. 31.
    Gomez-Tortosa E, Gonzalo I, Fanjul S et al (2003) Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. Arch Neurol 60(9):1218–1222CrossRefPubMedGoogle Scholar
  32. 32.
    Reiriz J, Mena MA, Bazan E et al (1989) Temporal profile of levels of monoamines and their metabolites in striata of rats implanted with dialysis tubes. J Neurochem 53(3):789–792CrossRefPubMedGoogle Scholar
  33. 33.
    Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bjorkqvist M (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington’s disease. Hum Mol Genet 20(11):2225–2237CrossRefPubMedGoogle Scholar
  34. 34.
    Hernandez-Torres G, Cipriano M, Heden E et al (2014) A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis. Angew Chem Int Ed Engl 53(50):13765–13770CrossRefPubMedGoogle Scholar
  35. 35.
    Bisogno T, Martire A, Petrosino S, Popoli P, Di Marzo V (2008) Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington’s disease. Neurochem Int 52(1–2):307–313CrossRefPubMedGoogle Scholar
  36. 36.
    Fernandez-Estevez MA, Casarejos MJ, Lopez Sendon J et al (2014) Trehalose reverses cell malfunction in fibroblasts from normal and Huntington’s disease patients caused by proteosome inhibition. PLoS One 9(2):e90202CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Battista N, Bari M, Tarditi A et al (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington’s disease mutation in peripheral lymphocytes. Neurobiol Dis 27(1):108–116CrossRefPubMedGoogle Scholar
  38. 38.
    Casarejos MJ, Perucho J, Gomez A et al (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis 35(3):525–539PubMedGoogle Scholar
  39. 39.
    Tapiola T, Alafuzoff I, Herukka SK et al (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66(3):382–389CrossRefPubMedGoogle Scholar
  40. 40.
    Giampa C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR (2013) Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington’s disease. PLoS One 8(5):e64037CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Zuccato C, Ciammola A, Rigamonti D et al (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 293(5529):493–498CrossRefPubMedGoogle Scholar
  42. 42.
    Chang KH, Chen YC, Wu YR, Lee WF, Chen CM (2012) Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington’s disease patients. PLoS One 7(9):e46492CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Sagredo O, Gonzalez S, Aroyo I et al (2009) Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington’s disease. Glia 57(11):1154–1167CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Butovsky E, Juknat A, Goncharov I et al (2005) In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. J Neurochem 93(4):802–811CrossRefPubMedGoogle Scholar
  45. 45.
    D’Souza DC, Pittman B, Perry E, Simen A (2009) Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 202(4):569–578CrossRefPubMedGoogle Scholar
  46. 46.
    De Petrocellis L, Ligresti A, Moriello AS et al (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 163(7):1479–1494CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Thieme D, Sachs H, Uhl M (2014) Proof of cannabis administration by sensitive detection of 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid in hair using selective methylation and application of liquid chromatography- tandem and multistage mass spectrometry. Drug Test Anal 6(1–2):112–118CrossRefPubMedGoogle Scholar
  48. 48.
    Blazquez C, Chiarlone A, Sagredo O et al (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain 134(Pt 1):119–136CrossRefPubMedGoogle Scholar
  49. 49.
    Van Laere K, Casteels C, Dhollander I et al (2010) Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo. J Nucl Med 51(9):1413–1417CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Jose Luis López-Sendón Moreno
    • 1
    • 6
    • 7
    Email author
  • Juan García Caldentey
    • 1
  • Patricia Trigo Cubillo
    • 1
  • Carolina Ruiz Romero
    • 2
  • Guillermo García Ribas
    • 1
  • M. A. Alonso Alonso Arias
    • 1
  • María Jesús García de Yébenes
    • 3
  • Rosa María Tolón
    • 4
  • Ismael Galve-Roperh
    • 5
    • 6
    • 7
  • Onintza Sagredo
    • 6
    • 7
    • 8
  • Sara Valdeolivas
    • 6
    • 7
    • 8
  • Eva Resel
    • 5
    • 6
    • 7
  • Silvia Ortega-Gutierrez
    • 9
  • María Laura García-Bermejo
    • 7
  • Javier Fernández Ruiz
    • 6
    • 7
    • 8
  • Manuel Guzmán
    • 5
    • 6
    • 7
  • Justo García de Yébenes Prous
    • 1
    • 6
  1. 1.Neurology DepartmentHospital Ramón y CajalMadridSpain
  2. 2.Neurobiology DepartmentHospital Ramón y CajalMadridSpain
  3. 3.Instituto de Salud MúsculoesqueléticaMadridSpain
  4. 4.Fundación Hospital de AlcorcónMadridSpain
  5. 5.Department of Biochemistry and Molecular Biology I, Faculty of BiologyComplutense UniversityMadridSpain
  6. 6.Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)MadridSpain
  7. 7.Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS)MadridSpain
  8. 8.Department of Biochemistry and Molecular Biology III, Faculty of MedicineComplutense UniversityMadridSpain
  9. 9.Department of Organic Chemistry I, Faculty of ChemistryComplutense UniversityMadridSpain

Personalised recommendations